Inventiva (NASDAQ:IVA) Now Covered by Piper Sandler

Key Points

• Piper Sandler has initiated coverage on Inventiva with an "overweight" rating and a price target of $26.00, suggesting a potential upside of 309.45% from the current stock price.
• Inventiva's stock has seen a 21.4% increase, trading at $6.35, with a one-year high of $6.50 and a low of $1.53.
• Institutional investors own about 19.06% of Inventiva's stock, with Wealth Enhancement Advisory Services LLC recently acquiring approximately 10,715 shares valued at around $32,000.

Equities research analysts at Piper Sandler began coverage on shares of Inventiva (NASDAQ:IVA - Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an "overweight" rating and a $26.00 price target on the stock. Piper Sandler's price objective would indicate a potential upside of 309.45% from the company's previous close.

Inventiva Trading Up 21.4%

Shares of IVA opened at $6.35 on Wednesday. Inventiva has a one year low of $1.53 and a one year high of $6.50. The company has a 50-day moving average of $3.59 and a two-hundred day moving average of $3.33.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.